Lyell Immunopharma Inc. reported a net loss of $140.7 million for the fourth quarter of 2025, a decline from $191.9 million in the same period last year, and a full‑year loss of $274.4 million, down from $343.0 million in 2024. Revenue for the quarter was $6,000 and $36,000 for the full year, reflecting the company’s early‑stage pipeline and the fact that it has not yet generated significant product sales.
Cash, cash equivalents and marketable securities stood at $247.2 million as of December 31, 2025, compared with $383.5 million at the end of 2024. The company closed a $50 million equity tranche on March 12, 2026, which has extended its cash runway to the second quarter of 2027, assuming no additional capital raises are required.
Lyell also reported clinical progress: seven patients with metastatic colorectal cancer have been dosed with its LYL273 candidate, and patient dosing has begun in the PiNACLE‑H2H Phase 3 trial of ronde‑cel versus investigator’s choice of axicabtagene ciloleucel or lisocabtagene maraleucel in relapsed or refractory large B‑cell lymphoma. These milestones position the company to potentially secure regulatory approvals and commercial launch for two CAR‑T products.
The narrowing of the net loss is largely attributable to lower in‑process research and development and stock‑based compensation expenses compared with the prior year, but the company remains in a high‑burn phase as it invests heavily in late‑stage clinical development. Revenue remains minimal, underscoring that Lyell’s business model is still in the pre‑commercial stage. The equity infusion and existing cash reserves provide a buffer, but the company will need to raise additional capital to sustain operations beyond Q2 2027.
Management indicated that the current reserves will support operations into the second quarter of 2027, pending further capital raises. The company’s focus remains on advancing its dual‑targeting CAR‑T platform, with the PiNACLE‑H2H trial and LYL273 dosing as key indicators of future commercial potential. Investors will watch the company’s ability to secure additional funding and to translate clinical milestones into revenue streams as the primary drivers of long‑term value.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.